Affinity maturation of antibodies assisted by in silico modeling

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 26, 2008, Pages 9029-9034

  Barderas, Rodrigo ^a   Desmet, Johan ^b   Timmerman, Peter ^c,d   Meloen, Rob ^c,e   Casal, J Ignacio ^a  

^a Centro Nacional de Investigations Oncológicas   (Spain)

^b Algonomics   (Belgium)

^c Pepscan Systems   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Antibody engineering; Gastrin; In vitro affinity maturation; Pancreatic cancer

Indexed keywords

GASTRIN; ANTIBODY; GASTRIN 17; MUTANT PROTEIN;

ANTIBODY AFFINITY; ARTICLE; BINDING SITE; CELL LINE; CELL PROLIFERATION; COMPUTER MODEL; METHODOLOGY; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MUTAGENESIS; PHAGE DISPLAY; PRIORITY JOURNAL; AMINO ACID SEQUENCE; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; COMPLEMENTARITY DETERMINING REGION; GENETICS; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; KINETICS; MOLECULAR GENETICS; MUTATION; SERODIAGNOSIS; TUMOR CELL LINE;

CITRUS MACROPHYLLA;

AMINO ACID SEQUENCE; ANTIBODIES; ANTIBODY AFFINITY; CELL LINE, TUMOR; CELL PROLIFERATION; COMPLEMENTARITY DETERMINING REGIONS; COMPUTATIONAL BIOLOGY; GASTRINS; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS; MUTANT PROTEINS; MUTATION; NEUTRALIZATION TESTS;

EID: 48249111382     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0801221105     Document Type: Article

References (43)

1. Finley GG, Koski RA, Melhem MF, Pipas JM, Meisler AI (1993) Expression of the gastringene in the normal human colon and colorectal adenocarcinoma. Cancer Res 53:2919-2926.
2. Goetze JP, Nielsen FC, Burcharth F, Rehfeld JF (2000) Closing the gastrin loop in pancreatic carcinoma: Coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer 88:2487-2494.
3. Henwood M, Clarke PA, Smith AM, Watson SA (2001) Expression of gastrin in developing gastric adenocarcinoma. Br J Surg 88:564-568.
4. Seva C, Dickinson CJ, Yamada T (1994) Growth-promoting effects of glycine-extended progastrin. Science 265:410-412.
5. Smith JP, Fantaskey AP, Liu G, Zagon IS (1995) Identification of gastrin as a growth peptide in human pancreatic cancer. Am J Physiol 268:R135-R141.
6. Gilliam AD, Watson SA (2007) G17DT: An antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther 7:397-404.
7. Smith AM, Justin T, Michaeli D, Watson SA (2000) Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer. Clin Cancer Res 6:4719-4724.
8. Brett BT, et al. (2002) Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 20:4225-4231.
9. Gilliam AD, et al. (2004) A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol 30:536-543.
10. Barderas R, et al. (2006)A fast mutagenesis procedure to recover soluble and functional scFvs containing amber stop codons from synthetic and semisynthetic antibody libraries. J Immunol Methods 312:182-189.
11. Barderas R, et al (2008) Designing antibodies for the inhibition of gastrin activity in tumoral cell lines. Int J Cancer 122:2351-2359.
12. Presta LG (2005) Selection, design, and engineering of therapeutic antibodies. J Allergy Clin Immunol 116:731-736.
13. Presta LG (2006) Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 58:640-656.
14. Cauerhff A, Goldbaum FA, Braden BC (2004) Structural mechanism for affinity maturation of an anti-lysozyme antibody. Proc Natl Acad Sci USA 101:3539-3544.
15. Rajpal A, et al. (2005)A general method for greatly improving the affinity of antibodies by using combinatorial libraries. Proc Natl Acad Sci USA 102:8466-8471.
16. Jain M, Kamal N, Batra SK (2007) Engineering antibodies for clinical applications. Trends Biotechnol 25:307-316.
17. Valjakka J, et al. (2002) Crystal structure of an in vitro affinity- and specificity-matured anti-testosterone Fab in complex with testosterone. Improved affinity results from small structural changes within the variable domains. J Biol Chem 277:44021-44027.
18. Tomlinson IM, et al. (1996) The imprint of somatic hypermutation on the repertoire of human germline V genes. J Mol Biol 256:813-817.
19. Clark LA, et al. (2006) Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci 15:949-960.
20. Fontayne A, et al. (2007) Paratope and epitope mapping of the antithrombotic antibody 6B4 in complex with platelet glycoprotein Ibalpha. J Biol Chem 282:23517-23524.
21. Fontayne A, et al. (2006) Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody: 6B4. Thromb Haemost 96:671-684.
22. Webster DM, Henry AH, Rees AR (1994) Antibody-antigen interactions. Curr Opin Struct Biol 4:123-129.
23. Cardoso RM, et al. (2005) Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22:163-173.
24. Yang WP, et al. (1995)CDRwalking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol 254:392-403.
25. Gura T (2002) Therapeutic antibodies: Magic bullets hit the target. Nature 417:584-586.
26. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147-1157.
27. Luginbuhl B, et al. (2006) Directed evolution of an anti-prion protein scFv fragment to an affinity of 1 pM and its structural interpretation. J Mol Biol 363:75-97.
28. Barbas CF, III, et al. (1994) In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci USA 91:3809-3813.
29. Ho M, Kreitman RJ, Onda M, Pastan I (2005) In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem 280:607-617.
30. Schier R, et al. (1996) Identification of functional and structural amino-acid residues by parsimonious mutagenesis. Gene 169:147-155.
31. Schier R, et al. (1996) Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 263:551-567.
32. Carter JM (1994) Epitope mapping of a protein using the Geysen (PEPSCAN) procedure. Methods Mol Biol 36:207-223.
33. Pantophlet R, et al. (2003) Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol 77:642-658.
34. Markland W, Roberts BL, Saxena MJ, Guterman SK, Ladner RC (1991) Design, construction and function of a multicopy display vector using fusions to the major coat protein of bacteriophage M13. Gene 109:13-19.
35. Ewert S, Honegger A, Pluckthun A (2004) Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods 34:184-199.
36. Adams GP, et al. (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61:4750-4755.
37. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343-357.
38. Delhaise P, Bardiaux M, Wodak S (1984) Interactive computer animation of macromolecules. J Mol Graphics 2:103-106.
39. Desmet J, Spriet J, Lasters I (2002) Fast and accurate side-chain topology and energy refinement (FASTER) as a new method for protein structure optimization. Proteins 48:31-43.
40. Barbas CF, Burton DR, Scott JK, Silverman GJ (2001) Phage Display: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
41. Kabat EA, Wu TT, Perry HM, Gottesmann KS, Foeller C (1991) Sequences of Proteins of Immunological Interest (National Institute Health, Bethesda, MD), 5th Ed.
42. Martinez-Torrecuadrada J, et al. (2005) Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 11:6280-6290.
43. Goletz S, et al. (2002) Selection of large diversities of antiidiotypic antibody fragments by phage display. J Mol Biol 315:1087-1097.